| epirubicin / Generic mfg. |
| Completed | 2 | 72 | Europe | Matuzumab, EMD 72000, Epirubicin, Cisplatin, Capecitabine | Merck KGaA, Darmstadt, Germany | Esophageal Cancer, Gastric Cancer | 07/08 | 08/08 | | |
NCT00220129: Neoadjuvant Epirubicin, Cisplatin and Capecitabine (ECX) Followed by Definitive Chemoradiation With/Without Surgery for Squamous Cell Carcinoma of the Oesophagus |
|
|
| Completed | 2 | 16 | Europe | Epirubicin, Cisplatin, Capecitabine, Surgical Resection | Royal Marsden NHS Foundation Trust | Oesophageal Carcinoma | | | | |
NCT00220103: Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma |
|
|
| Completed | 2 | 80 | Europe | epirubicin, capecitabine, cisplatin, Surgical resection | Royal Marsden NHS Foundation Trust | Adenocarcinoma of Oesophagus | | | | |
NCT00601705: Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach |
|
|
| Completed | 2 | 61 | US | cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 03/12 | 01/15 | | |
NCT01710592 / 2006-003332-29: A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer |
|
|
| Completed | 2 | 35 | Europe | Epirubicin, Oxaliplatin, Capecitabine, Docetaxel | Cancer Trials Ireland | Gastro Oesophageal Cancer | 12/12 | | | |
NCT01123473 / 2009-011580-36: Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer |
|
|
| Terminated | 2 | 29 | Europe | capecitabine, cisplatin, epirubicin hydrochloride, fluorouracil, lapatinib ditosylate | European Organisation for Research and Treatment of Cancer - EORTC | Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer | 08/13 | 09/14 | | |
|
NCT00737438: Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma |
|
|
| Completed | 2 | 22 | US | epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan, Patients who have a poor PET response to cycle 1 of ECX plus bevacizumab, (eg. < 35% FDG reduction on the week 3 PET scan compared with baseline), will be switched to salvage therapy of docetaxel and irinotecan (DI)., This treatment will be administered on week 1 and 2 of a 3, week cycle for 2 cycles. Patients will receive bevacizumab for the 1st cycle, of salvage docetaxel/irinotecan only. There is again a planned 10-12 week time, interval (eg. 70-84 days) between the last bevacizumab treatment and surgery. | Memorial Sloan Kettering Cancer Center, Genentech, Inc., Weill Medical College of Cornell University | Esophageal Cancer, Gastric Cancer | 02/15 | 02/15 | | |
|
NCT01830270: Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer |
|
|
| Terminated | 2 | 30 | Europe | Epirubicin, Cisplatin, Paclitaxel, gastric surgery | Centre Hospitalier Universitaire de Besancon | Stomach Neoplasms, Oesophageal Junction Cancer, Lower Oesophagus Cancer | 04/15 | 07/16 | | |
| Terminated | 2 | 21 | Europe | Omegaven, Omega-3 fish oil | University Hospitals, Leicester | Esophageal Neoplasm, Gastric Neoplasm | 12/15 | 12/15 | | |
| Completed | 1b/2 | 130 | US, Canada, Europe, RoW | Capecitabine, Xeloda, Epirubicin, AMG 102, Cisplatin, Placebo | Amgen | Esophagogastric Junction Adenocarcinoma, Gastric Cancer, Esophageal Cancer | 11/10 | 06/13 | | |
|
|
|
|
NCT00021047: Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor |
|
|
| Completed | 1/2 | | US | capecitabine, carboplatin, epirubicin hydrochloride | National Institutes of Health Clinical Center (CC), National Cancer Institute (NCI) | Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific | | 06/04 | | |
NCT00130936: Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates |
|
|
| Terminated | 1/2 | 50 | Canada | Epirubicin, Carboplatin, Capecitabine | AHS Cancer Control Alberta | Gastric Cancer, Esophageal Cancer, Tumors | | 11/07 | | |
EOXP, NCT00667420: Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma |
|
|
| Terminated | 1/2 | 17 | US | panitumumab, epirubicin, oxaliplatin, xeloda | Massachusetts General Hospital | Esophageal Adenocarcinoma, Gastric Adenocarcinoma | 06/11 | 06/14 | | |
